Europe Esoteric Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)
The Europe Esoteric Testing Market size is estimated at USD 7.80 billion in 2024, and is expected to reach USD 13.23 billion by 2029, growing at a CAGR of 11.23% during the forecast period (2024-2029).
The European esoteric testing market is anticipated to grow with the rising burden of chronic diseases, rare diseases, and increasing research expenditure. The rising prevalence of chronic illnesses and uncommon ailments in Europe is spurring the need for specialized testing. The widespread occurrence of diseases such as cancer, infectious agents, and unusual genetic conditions calls for cutting-edge diagnostic techniques to enable precise and timely recognition, contributing to market growth.
The region has an increasing burden of several chronic and rare diseases that require esoteric testing to be diagnosed on time. For instance, as per the International Diabetes Federation (IDF), in February 2022, over 4.47 million adults were reported to have diabetes in the total adult population in Italy, which was equivalent to a prevalence rate of 9.9%. It was also stated that over 1.2 million children and adolescents aged 19 years or less were reported to have type-1 diabetes. Thus, the growing burden of type I and type II diabetes is expected to increase demand for diagnosis with esoteric testing, which is likely to support the growth of the market.
Similarly, according to the data updated by the Spanish Network of Cancer Registries (REDECAN) in January 2023, approximately 279,260 new cases of cancer were expected to occur in Spain by the end of 2023, out of which 42,721 new cases of colorectal cancer, 31,282 cases of lung cancer, and 21,694 cases of urinary bladder cancer. Thus, with the vast patient base of chronic patients, the demand for esoteric tests is expected to increase for the timely or early diagnosis of underlying diseases, boosting the market’s growth during the forecast period.
Furthermore, recent developments by service providers are expected to increase the availability of esoteric testing in the region, which is likely to boost the market’s growth. For instance, in April 2022, Minaris Medical obtained the European Union In Vitro Diagnostic Medical Devices Regulation certification for fecal occult blood test reagents. Similarly, in November 2023, Arup Laboratories achieved the Conformitй Europйenne (CE) certification for the single-site use of AAV5 DetectCDx, aligning with the European Union's In Vitro Diagnostic Medical Devices Regulation. Developed in collaboration with BioMarin Pharmaceutical Inc., AAV5 DetectCDx functions as a companion diagnostic, aiding in the identification of adult patients eligible for BioMarin's groundbreaking gene therapy for severe hemophilia A, valoctocogene roxaparvovec-rvox (ROCTAVIAN). Thus, the launch and approval of innovative esoteric tests in the market are expected to contribute to the market's growth during the forecast period.
Therefore, owing to the factors above, the market studied is anticipated to grow during the forecast period. However, the stringent regulatory scenario is likely to impede the market’s growth.
Europe Esoteric Testing Market Trends
Oncology Segment is Expected to Exhibit Significant Market Growth During the Forecast Period
The segment includes esoteric testing in Europe for cancer diagnosis by detecting multiple tumor markers with high throughput and easy operation at an affordable cost. Under esoteric tests, a few in-vitro techniques can be used to measure antibody levels specific to cancers.
The segment is anticipated to grow during the forecast period owing to the high burden of cancer and increasing demand for early diagnosis and treatment for cancer. For instance, according to the Cancer Research United Kingdom data published in May 2023, the average annual number of new cancer cases in the United Kingdom was estimated to increase from approximately 420,000 during 2023-2025 to approximately 506,000 during 2038-2040. The combined incidence rate of all cancers in the United Kingdom was projected to rise by 2% from 2023-2025 to 2038-2040, reaching an average of 625 cases per 100,000 people per year during 2038-2040. Thus, the high prevalence of diseases like cancer necessitates advanced diagnostic testing methods for accurate and early detection, contributing to the segment’s growth.
Furthermore, research studies published by European researchers have underlined the high demand for esoteric tests in Europe. For instance, a study published in the National Cancer Institute (NCI) by European researchers in September 2022 underlined that the biennial fecal occult blood screening on colorectal cancer in England had reduced the number of mortalities caused by the disease. Thus, the benefits offered by the esoteric testing of diseases in Europe are anticipated to boost the segment's growth in the coming years. Therefore, the factors mentioned above are expected to drive the development of the segment.
The increasing awareness about the importance of early cancer detection has led to the adoption of esoteric tests among healthcare professionals. In May 2023, the EU Beating Cancer Plan prioritized cancer prevention, early detection, diagnosis, treatment, and patient well-being. This initiative aimed to enhance access to cancer screening, data management, and the quality of screening programs across Europe, strongly emphasizing reducing inequalities and leveraging technology for better outcomes.
Thus, the growing burden of cancer, several government initiatives, and increasing research and development activities are expected to boost the segment's growth during the forecast period.
The United Kingdom is Expected to Witness Significant Growth During the Forecast Period
The United Kingdom is expected to witness significant growth during the forecast period owing to the advanced medical infrastructure, the high burden of chronic diseases, and the recent developments by market players. For instance, according to data published by University College London in October 2023, by 2040, England and Wales were projected to experience a significant increase in dementia prevalence, with 1.7 million individuals affected in England alone, exceeding previous estimates. NHS data released in November 2023 revealed a surge in dementia diagnoses, with 475,573 people identified in September 2023, representing a rise of over 52,000 from the previous year.
Further, according to data published by the UK government in 2022, more than 7,000 rare diseases affected 3.5 million people in the United Kingdom in 2022. The same source further stated that these diseases have a complex nature, which makes their diagnosis challenging. In such a scenario, esoteric tests can be beneficial to diagnose the tracer amount of the target disease antigen or run highly specialized esoteric diagnostic tests.
Furthermore, the increasing research for early diagnosis of chronic diseases such as cancer by using esoteric tests is expected to elevate the demand for esoteric diagnostic tests, boosting the market's growth during the forecast period. For instance, a study published by the University of Oxford in Clinical Cancer Research in 2022 mentioned a new blood-based test that uses nuclear magnetic resonance (NMR) metabolomics and is the first ever to simultaneously identify if a patient has cancer and if it has spread. Thus, with such advancing research, more market players will be attracted to offer such advanced esoteric cancer testing for an early diagnosis. Therefore, advancing research in esoteric diagnosis is expected to boost market growth in the country.
Thus, the market is a high burden of chronic and growing research and development and is expected to witness significant growth in the United Kingdom during the forecast period due to the abovementioned factors.
Europe Esoteric Testing Industry Overview
The European esoteric testing market is fragmented in nature due to the presence of several service providers operating regionally. The market players adopted several strategies, such as expansion, acquisition, and new product launches, to stay competitive in the market. The leading players operating in the market include Eurofins Scientific, Nordic Laboratories, Buhlmann Diagnostics Corp, ACM Global Laboratories, and Medical Laboratory Bremen.
Additional Benefits:
The market estimate (ME) sheet in Excel format
3 months of analyst support
The European esoteric testing market is anticipated to grow with the rising burden of chronic diseases, rare diseases, and increasing research expenditure. The rising prevalence of chronic illnesses and uncommon ailments in Europe is spurring the need for specialized testing. The widespread occurrence of diseases such as cancer, infectious agents, and unusual genetic conditions calls for cutting-edge diagnostic techniques to enable precise and timely recognition, contributing to market growth.
The region has an increasing burden of several chronic and rare diseases that require esoteric testing to be diagnosed on time. For instance, as per the International Diabetes Federation (IDF), in February 2022, over 4.47 million adults were reported to have diabetes in the total adult population in Italy, which was equivalent to a prevalence rate of 9.9%. It was also stated that over 1.2 million children and adolescents aged 19 years or less were reported to have type-1 diabetes. Thus, the growing burden of type I and type II diabetes is expected to increase demand for diagnosis with esoteric testing, which is likely to support the growth of the market.
Similarly, according to the data updated by the Spanish Network of Cancer Registries (REDECAN) in January 2023, approximately 279,260 new cases of cancer were expected to occur in Spain by the end of 2023, out of which 42,721 new cases of colorectal cancer, 31,282 cases of lung cancer, and 21,694 cases of urinary bladder cancer. Thus, with the vast patient base of chronic patients, the demand for esoteric tests is expected to increase for the timely or early diagnosis of underlying diseases, boosting the market’s growth during the forecast period.
Furthermore, recent developments by service providers are expected to increase the availability of esoteric testing in the region, which is likely to boost the market’s growth. For instance, in April 2022, Minaris Medical obtained the European Union In Vitro Diagnostic Medical Devices Regulation certification for fecal occult blood test reagents. Similarly, in November 2023, Arup Laboratories achieved the Conformitй Europйenne (CE) certification for the single-site use of AAV5 DetectCDx, aligning with the European Union's In Vitro Diagnostic Medical Devices Regulation. Developed in collaboration with BioMarin Pharmaceutical Inc., AAV5 DetectCDx functions as a companion diagnostic, aiding in the identification of adult patients eligible for BioMarin's groundbreaking gene therapy for severe hemophilia A, valoctocogene roxaparvovec-rvox (ROCTAVIAN). Thus, the launch and approval of innovative esoteric tests in the market are expected to contribute to the market's growth during the forecast period.
Therefore, owing to the factors above, the market studied is anticipated to grow during the forecast period. However, the stringent regulatory scenario is likely to impede the market’s growth.
Europe Esoteric Testing Market Trends
Oncology Segment is Expected to Exhibit Significant Market Growth During the Forecast Period
The segment includes esoteric testing in Europe for cancer diagnosis by detecting multiple tumor markers with high throughput and easy operation at an affordable cost. Under esoteric tests, a few in-vitro techniques can be used to measure antibody levels specific to cancers.
The segment is anticipated to grow during the forecast period owing to the high burden of cancer and increasing demand for early diagnosis and treatment for cancer. For instance, according to the Cancer Research United Kingdom data published in May 2023, the average annual number of new cancer cases in the United Kingdom was estimated to increase from approximately 420,000 during 2023-2025 to approximately 506,000 during 2038-2040. The combined incidence rate of all cancers in the United Kingdom was projected to rise by 2% from 2023-2025 to 2038-2040, reaching an average of 625 cases per 100,000 people per year during 2038-2040. Thus, the high prevalence of diseases like cancer necessitates advanced diagnostic testing methods for accurate and early detection, contributing to the segment’s growth.
Furthermore, research studies published by European researchers have underlined the high demand for esoteric tests in Europe. For instance, a study published in the National Cancer Institute (NCI) by European researchers in September 2022 underlined that the biennial fecal occult blood screening on colorectal cancer in England had reduced the number of mortalities caused by the disease. Thus, the benefits offered by the esoteric testing of diseases in Europe are anticipated to boost the segment's growth in the coming years. Therefore, the factors mentioned above are expected to drive the development of the segment.
The increasing awareness about the importance of early cancer detection has led to the adoption of esoteric tests among healthcare professionals. In May 2023, the EU Beating Cancer Plan prioritized cancer prevention, early detection, diagnosis, treatment, and patient well-being. This initiative aimed to enhance access to cancer screening, data management, and the quality of screening programs across Europe, strongly emphasizing reducing inequalities and leveraging technology for better outcomes.
Thus, the growing burden of cancer, several government initiatives, and increasing research and development activities are expected to boost the segment's growth during the forecast period.
The United Kingdom is Expected to Witness Significant Growth During the Forecast Period
The United Kingdom is expected to witness significant growth during the forecast period owing to the advanced medical infrastructure, the high burden of chronic diseases, and the recent developments by market players. For instance, according to data published by University College London in October 2023, by 2040, England and Wales were projected to experience a significant increase in dementia prevalence, with 1.7 million individuals affected in England alone, exceeding previous estimates. NHS data released in November 2023 revealed a surge in dementia diagnoses, with 475,573 people identified in September 2023, representing a rise of over 52,000 from the previous year.
Further, according to data published by the UK government in 2022, more than 7,000 rare diseases affected 3.5 million people in the United Kingdom in 2022. The same source further stated that these diseases have a complex nature, which makes their diagnosis challenging. In such a scenario, esoteric tests can be beneficial to diagnose the tracer amount of the target disease antigen or run highly specialized esoteric diagnostic tests.
Furthermore, the increasing research for early diagnosis of chronic diseases such as cancer by using esoteric tests is expected to elevate the demand for esoteric diagnostic tests, boosting the market's growth during the forecast period. For instance, a study published by the University of Oxford in Clinical Cancer Research in 2022 mentioned a new blood-based test that uses nuclear magnetic resonance (NMR) metabolomics and is the first ever to simultaneously identify if a patient has cancer and if it has spread. Thus, with such advancing research, more market players will be attracted to offer such advanced esoteric cancer testing for an early diagnosis. Therefore, advancing research in esoteric diagnosis is expected to boost market growth in the country.
Thus, the market is a high burden of chronic and growing research and development and is expected to witness significant growth in the United Kingdom during the forecast period due to the abovementioned factors.
Europe Esoteric Testing Industry Overview
The European esoteric testing market is fragmented in nature due to the presence of several service providers operating regionally. The market players adopted several strategies, such as expansion, acquisition, and new product launches, to stay competitive in the market. The leading players operating in the market include Eurofins Scientific, Nordic Laboratories, Buhlmann Diagnostics Corp, ACM Global Laboratories, and Medical Laboratory Bremen.
Additional Benefits:
The market estimate (ME) sheet in Excel format
3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Burden of Chronic Diseases and Rare Diseases
4.2.2 Increasing Research Expenditure
4.3 Market Restraints
4.3.1 Stringent Regulatory Framework
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (MARKET SIZE BY VALUE - USD)
5.1 By Test Type
5.1.1 Endocrinology
5.1.2 Infectious Disease
5.1.3 Oncology
5.1.4 Neurology
5.1.5 Toxicology
5.1.6 Other Test Types
5.2 By Technology
5.2.1 Flow Cytometry
5.2.2 Chemiluminescence Immunoassay
5.2.3 Mass Spectrometry
5.2.4 Radio Immunoassay
5.2.5 Other Technologies
5.3 By Geography
5.3.1 Germany
5.3.2 United Kingdom
5.3.3 France
5.3.4 Italy
5.3.5 Spain
5.3.6 Rest of Europe
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 ACM Global Laboratories
6.1.2 Foundation Medicine
6.1.3 Arup Laboratories
6.1.4 Exact Sciences
6.1.5 Miraca Holdings Inc.
6.1.6 Myriad Genetics Inc.
6.1.7 Nordic Laboratories
6.1.8 OPKO Health Inc.
6.1.9 Quest Diagnostics Inc.
6.1.10 Eurofins Scientific
6.1.11 Buhlmann Diagnostics Corp.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Burden of Chronic Diseases and Rare Diseases
4.2.2 Increasing Research Expenditure
4.3 Market Restraints
4.3.1 Stringent Regulatory Framework
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (MARKET SIZE BY VALUE - USD)
5.1 By Test Type
5.1.1 Endocrinology
5.1.2 Infectious Disease
5.1.3 Oncology
5.1.4 Neurology
5.1.5 Toxicology
5.1.6 Other Test Types
5.2 By Technology
5.2.1 Flow Cytometry
5.2.2 Chemiluminescence Immunoassay
5.2.3 Mass Spectrometry
5.2.4 Radio Immunoassay
5.2.5 Other Technologies
5.3 By Geography
5.3.1 Germany
5.3.2 United Kingdom
5.3.3 France
5.3.4 Italy
5.3.5 Spain
5.3.6 Rest of Europe
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 ACM Global Laboratories
6.1.2 Foundation Medicine
6.1.3 Arup Laboratories
6.1.4 Exact Sciences
6.1.5 Miraca Holdings Inc.
6.1.6 Myriad Genetics Inc.
6.1.7 Nordic Laboratories
6.1.8 OPKO Health Inc.
6.1.9 Quest Diagnostics Inc.
6.1.10 Eurofins Scientific
6.1.11 Buhlmann Diagnostics Corp.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
